Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine‐induced peripheral neuropathy in patients with lymphoma

Azoulay, David; Nasser, Roni; Sharon, Rivka; Simanovich, Liya; Akria, Luiza; Shaoul, Ety; Horowitz, Netanel A.

doi:10.1111/bjh.15428

Cited by 8 publications

(6 citation statements)

References 10 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eaton et al demonstrated this in an animal study by successfully producing significant analgesic effects by genetically inducing overexpression of BDNF in rats (Eaton et al, 2002). In a related study, Azoulay and colleagues identified low serum BDNF levels in patients with peripheral neuropathic pain (Azoulay et al, 2020), which was consistent with their previous findings in lymphoma and myeloma patients (Azoulay et al, 2019; Azoulay et al, 2019), implying that lower BDNF levels could be linked to hyperalgesia.…”

supporting

confidence: 71%

The Relationship Between Plasma BDNF and Pain in Older Adults With Knee Osteoarthritis

Sorkpor

Galle

Teixeira

et al. 2021

Biological Research For Nursing

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most prevalent cause of chronic pain and disability in people aged ≥45 years, with the knee being the most affected joint. Neurotrophic factors like brain-derived neurotrophic factor (BDNF), which promotes neurogenesis and neuroplasticity, have been shown to significantly affect chronic pain. This study aimed to investigate the relationship between resting plasma BDNF levels and clinical pain and quantitative sensory testing measures in older adults with knee OA pain. For this secondary analysis, a previously reported dataset was used comprised of older adults with knee OA who underwent quantitative sensory testing. A comprehensive generalized linear model (GLM) was built to understand the relationships between BDNF and important covariates, followed by the elastic net (EN) method for variable selection. GLM was then performed to regress BDNF levels against only the variables selected by EN. The mean age of the sample was 60.4 years ( SD = 9.1). Approximately half of the participants were female (53%). Plasma BDNF levels were positively associated with heat pain threshold and the numeric rating scale of pain. Future mechanistic studies are needed to replicate and extend these findings to advance our knowledge of the underlying mechanisms of BDNF in knee OA and other chronic pain conditions.

show abstract

supporting

confidence: 71%

The Relationship Between Plasma BDNF and Pain in Older Adults With Knee Osteoarthritis

Sorkpor

Galle

Teixeira

et al. 2021

Biological Research For Nursing

View full text Add to dashboard Cite

show abstract

“…Another study demonstrated a direct correlation between the level of BDNF and the combined score for diabetes-related peripheral neuropathy, which is a known risk factor for CIPN 16. Preliminary studies by our group showing a link between CIPN and BDNF protein levels in blood171819-emphasize the need for further investigations of BDNF as a potential biomarker for CIPN. The current study aimed to determine the associations of serum BDNF protein levels and the Val66Met SNP with the development of CIPN in NHL and MM patients.…”

Section: Introductionmentioning

confidence: 88%

Prediction of Chemotherapy-Induced Peripheral Neuropathy in Patients with Lymphoma and Myeloma: the Roles of Brain-Derived Neurotropic Factor Protein Levels and A Gene Polymorphism

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background and PurposeBrain-derived neurotrophic factor (BDNF) is a neuronal growth factor that plays an essential role in the maintenance of the nervous system. We have evaluated the peripheral blood protein levels of BDNF and the valine-to-methionine substitution at codon 66 (Val66Met) single-nucleotide polymorphism (SNP) as potential biomarkers for the early recognition of chemotherapy-induced peripheral neuropathy (CIPN) in non-Hodgkin lymphoma and multiple myeloma patients.MethodsCIPN was assessed in 45 patients at the diagnosis and during vincristine or bortezomib-based therapy using objective [reduced version of the Total Neuropathy Score (TNSr)] and subjective (FACT-GOG-NTx) tools. Depression was assessed using the Patient Health Questionnaire-9 (PHQ-9) questionnaire. BDNF protein levels and the Val66Met SNP were determined using ELISA and Sanger sequencing.ResultsThe pretreatment BDNF protein level was inversely correlated with the maximum TNSr, FACT-GOG-NTx, and PHQ-9 scores in both genotypes. BDNF patients with the Val/Val genotype demonstrated significantly higher maximum FACT-GOG-NTx and PHQ-9 scores than those with the Val/Met and Met/Met genotypes (Met-BNDF carriers). Correlations between PHQ-9 and TNSr score were found only in Met-BDNF carriers, suggesting that peripheral neuropathy and depression coincide in Met-BDNF carriers.ConclusionsDetermining the BDNF protein levels before initiating chemotherapy might be a useful tool for CIPN risk assessment and preemptive dose modification. The present data should be validated in larger studies that include other neurotoxic agents.

show abstract

“…Similarly in 91 multiple myeloma patients treated with bortezomib or thalidomide lower BDNF levels during treatment were associated with CIPN by Common Terminology Criteria for Adverse Events (CTCAE), and a cut-point of 9.11 ng/ml was 76% sensitive and 71.4% specific to identify CIPN ( 17 ). Correlation between BDNF levels and CIPN by TNS-r was also reported in 22 non-Hodgkin lymphoma patients treated with vincristine ( 18 ).…”

Section: Protein/molecular Biomarkers Of Cipnmentioning

confidence: 62%

“…A study of 35 breast cancer patients treated with taxanes, however, found the risk may be due to increased prevalence of baseline neuropathy, with no difference in prevalence of CIPN between genotypes when excluding patients with baseline neuropathy ( 21 ). There was also no association between the met-BDNF genotype and CIPN in 22 non-Hodgkin lymphoma patients treated with vincristine ( 18 ).…”

Section: Protein/molecular Biomarkers Of Cipnmentioning

confidence: 95%

Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions

et al. 2022

View full text Add to dashboard Cite

Chemotherapy induced peripheral neuropathy (CIPN) is an often severe and debilitating complication of multiple chemotherapeutic agents that can affect patients of all ages, across cancer diagnoses. CIPN can persist post-therapy, and significantly impact the health and quality of life of cancer survivors. Identifying patients at risk for CIPN is challenging due to the lack of standardized objective measures to assess for CIPN. Furthermore, there are no approved preventative treatments for CIPN, and therapeutic options for CIPN remain limited once it develops. Biomarkers of CIPN have been studied but are not widely used in clinical practice. They can serve as an important clinical tool to identify individuals at risk for CIPN and to better understand the pathogenesis and avenues for treatment of CIPN. Here we review promising biomarkers of CIPN in humans and their clinical implications.

show abstract

Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine‐induced peripheral neuropathy in patients with lymphoma

Cited by 8 publications

References 10 publications

The Relationship Between Plasma BDNF and Pain in Older Adults With Knee Osteoarthritis

The Relationship Between Plasma BDNF and Pain in Older Adults With Knee Osteoarthritis

Prediction of Chemotherapy-Induced Peripheral Neuropathy in Patients with Lymphoma and Myeloma: the Roles of Brain-Derived Neurotropic Factor Protein Levels and A Gene Polymorphism

Biomarkers of Chemotherapy-Induced Peripheral Neuropathy: Current Status and Future Directions

Contact Info

Product

Resources

About